In silico identification of novel metabolic anti-angiogenic targets via public data mining and genome-scale metabolic modeling.

Current clinical anti-angiogenic therapies target growth factor signaling but suffer from resistance. Metabolism recently emerged as a new target to treat pathological blood vessel formation (angiogenesis) in cancer and eye disease. However, it is still unclear which metabolic enzymes are good anti-angiogenic targets. In this project I will construct a generic genome-scale metabolic model of human and mouse endothelial cells (ECs). I will specify these generic models to a tumor endothelial cell (TEC) model using transcriptomics and metabolomics data. I will use the TEC genome-scale model to predict in silico which metabolic enzymes are potential anti-angiogenic targets.status: publishe